By Kyle Morris

AstraZeneca PLC said Monday that a Phase 3 trial has shown that Enhertu reduced the risk of breast cancer progression or death by 50% when compared with chemotherapy in patients with HER2-low metastatic breast cancer with HR-positive and HR-negative disease forms.

The Anglo-Swedish pharmaceutical company said that Enhertu, or trastuzumab deruxtecan, met its primary endpoint of progression-free survival in patients with hormone receptor-positive disease, reducing the risk of disease progression or death by 49% versus chemotherapy.

Enhertu improved median overall survival by more than six months compared with chemotherapy in all patients evaluated, it said.

HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of many types of tumors, including breast, and is a biomarker expressed in breast cancer tumors.

Write to Kyle Morris at kyle.morris@dowjones.com

(END) Dow Jones Newswires

June 06, 2022 02:42 ET (06:42 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Astrazeneca.